Viral Vectors and Plasmid DNA Manufacturing Market Size is projected to reach USD 9.87 Billion by 2030, growing at a CAGR of 14.71%: Straits Research
September 22, 2022 12:05 ET
|
Straits Research
New York, United States, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vectors are instruments that are used to carry genetic material into cells, and viral vectors are one such tool. Viruses have developed...
AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing with Starting Material
February 08, 2022 19:00 ET
|
AGC Biologics
Heidelberg, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded...
AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer
November 01, 2021 09:03 ET
|
AGC Biologics
Seattle, Nov. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Jean-Baptiste Agnus has been...
Cytovance Biologics announces Plasmid DNA Manufacturing: An Optimized Platform Process Webinar
June 14, 2021 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, June 14, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy...
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
June 07, 2021 10:06 ET
|
AGC Biologics
Seattle, June 07, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech...
Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing
March 08, 2021 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and...
Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing
November 30, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and...
Cytovance Biologics Announces Bin Zhang as Chief Executive Officer
November 09, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics,...
Cytovance Biologics Announces an Investment in Mass Spectrometry Services
July 15, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, July 15, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass...
Cytovance Biologics Promotes John Mott to Vice President of Development
July 13, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, July 13, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the promotion of Dr. John...